Conditions: HIV Infections Hepatic Impairment
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 21
Healthy volunteers: no

Brief summary:
The purpose of the study was to assess the steady-state pharmacokinetics (PK) of efavirenz (EFV) in human immunodeficiency virus type 1 (HIV-1) infected subjects on stable antiretroviral regimens containing EFV, and having selected degrees of hepatic impairment or normal hepatic function.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: efavirenz containing antiretroviral regimen intervention 2: efavirenz containing antiretroviral regimen intervention 3: efavirenz containing antiretroviral regimen intervention 4: efavirenz containing antiretroviral regimen
Intervention descriptions: intervention 1: Capsule or Tablet, Oral, once daily for 2 days intervention 2: Capsule or Tablet, Oral, once daily for 2 days intervention 3: Capsule or Tablet, Oral, once daily for 2 days intervention 4: Capsule or Tablet, Oral, once daily for 2 days

Protocol document: